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ABSTRACT 
Neuroleptic induced neurological side effects were compared over a period of one year 
(1991-1992) in 45 schizophrenics and age and sex matched 42 mood disorder patients, diagnosed 
as per DSM-III-R criteria. Prevalence of dystonia was equally common in both groups. 
Pseudoparkinsonism was significantly high in female mood disorder patients, akathisia in middle 
aged mood disorder patients and tradive dyskinesia in mood disorder patients. Factors like age of 
onset, time of onset and mean dose of antipsychotics (chlorpromazine equivalent) did not show 
any significant difference. The findings are discussed in relation to their practical application and 
suggestions for future studies are outlined. 
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The side effects of neuroleptic drugs, 
both immediate and tardive are commonly 
encountered in clinical practice and cause 
concern to the patients and the psychiatrist.They 
are broadly classified as extrapyramidal 
syndrome which consists of pseudoparkinso-
nism, dystonia and akathisia and tradive 
syndromes of which the commonest is tardive 
dyskinesia. Despite the ubiquitous nature, 
estimates of their occurrence vary (Caesey and 
Keepers, 1988). 
Acute dystonia is reported to be the least 
common with an incidence of 5% which can go 
up to 50% with more potent neuroleptics. It 
occurs within hours to several days after initiat-
ing the treatment and twice commonly in males. 
An age predisposition has also been suggested 
with a preponderance in young, adults and 
children (Cunningham Owens, 1990).For 
pseudoparkinsonism an overall prevalence of 
25% has been reported. It may begin within 
several days of starting the treatment and is 
apparent within 30-50 days of initiating the 
treatment. Unlike dystonia,pseudoparkinsonism 
shows a rise in incidence after the age of 40 
especially females (Addonizio and 
Alexopoulose, 1988). Akathisia has a reported 
rate of 5-50% in routine clinical practice. It 
usually begins within several days of onset of 
treatment and 90% occurs within 2-3 months. 
It is reported that middle aged women are at 
increased risk for akathisia (Adleret al., 1989). 
Though a high rate of prevalence (50%) has 
been reported for TD, clinically significant TD 
occurs in at least 10-20% of all patients 
exposed to neuroleptics for more than a year. 
Older age and female sex appears to be a risk 
factor for TD (Jeste and Caligiri, 1993 & Dutta 
et al., 1995). 
An interesting finding to emerge in 
recent years from TD research is that patients 
with mood disorders may be more vulnerable 
to the development of TD than patients with 
schizophrenia (Mukherjee et al., 1986; Caesey, 
1988). It is not clear whether a similar differ-
ence exists for other side effects. In a 
retrospective file review study, Nasrallah et al. 
(1988) found that acute dystonia is more 
common in mania than schizophrenia. Studies 
by Remington et al. (1990), Khanna et al. (1992) 
110 NEUROLEPTIC INDUCED NEUROLOGICAL SIDE EFFECTS IN SCHIZOPHRENIA & MDP 
and Pandey et al. (1992) do not support this 
finding. So far no studies have reported a 
differential side effect profile for other side 
effects in schizophrenia and mood disorders. 
Considering these possibilities a study was 
planned with the following aims: 
-to assess the prevalence of dystonia, akathisia, 
and tardive dyskinesia over a period of 1 year, 
in schizophrenia and mood disorder patients., 
-to compare the clinical profile of patients .who 
develop these side effects such as age, sex, 
time of onset and the cumulative dosage of 
neuroleptics in schizophrenia and mood disor-
der. 
MATERIAL AND METHOD 
The study was conducted at the Depart-
ment of Psychiatry, Christian Medical College, 
Vellore. The hospital maintains detailed case 
records of all patients treated either as 
outpatients or as inpatients. Case records of all 
patients who received a diagnosis of schizo-
phrenia or bipolar affective disorders as per 
DSM- lll-R criteria (APA, 1987) over a period 
of 2 years (June 1989 to May 1991) were re-
viewed and those who had been followed up 
for a period of 12 months or more were evalu-
ated in detail. The exclusion criteria were : 
1) Presence of mental retardation, organic brain 
involvement or movement disorder by history, 
examination or investigations. 
2) Patients in whom doubts about the initial di-
agnosis of schizophrenia or mood disorder were 
entertained later. 
3) Patients who had been on neuroleptic treat-
ment prior to the consultation in hospital. 
4) Patients in whom there were gaps in follow-
up for a period of 3 months or more. 
After the exclusion criteria were applied, 
there were 45 patients with a diagnosis of 
schizophrenia. They were matched forage and 
sex with bipolar affective disorder patients of 
the same period. However, matched bipolar 
patients could not be obtained for 3 schizo-
phrenic patients, so that the number of bipolar 
patients were only 42. The records of all 87 
patients were evaluated and the following 
details were documented in a special proforma 
designed for this study : -
I) Sociodemographic and clinical profile. 
II) Information about the side effect such as the 
presence, type, time of onset and cumulative 
dose of neuroleptics received (in chlorpro-
mazine equivalent). The data were analysed by 
TABLE 
NEUROLEPTIC INDUCED NEUROLOGICAL SIDE 
EFFECTS PROFILE OF PATIENTS WITH SCHIZO-
PHRENIA AND MOOD DISORDERS 
Dystonia (total prevalence 
Prevalence (%) 
Mean age of onset (yrs) 
Gender (% Male) 
(% Female) 
Time of onset (days) 
Mean chlorpromazine 
equivalent (gm) 
Parkinsonism 
(total prevalence 54%) 
Prevalence (%) 
Mean age of onet (yrs) 
Gender (% Male) 
(% Female) 
Time of onset (days) 
Mean Chlorpromazine 
equivalent (gm) 
Schizo-
phrenia 
(N=45) 
™h.7 
26 
13.3 
4.4 
2.02 
1489 
60 
27.8 
37.7 
22.2 
17.14 
1779 
Akathisia (total prevalence 25%) 
Prevalence (%) 
Mean age of onset (yrs) 
Gender (% Male) 
(% Female) 
Time of onset (days) 
Mean chlorpromazine 
equivalent (gm) 
Tardive dyskinesia 
(total prevalence 17%) 
Prevalence (%) 
Mean age of onset (yrs) 
Gender (% Male) 
(% Female) 
Time of onset (months) 
Mean chlorpromazine 
28.8 
25.1 
24.4 
6.6 
17.98 
2268 
6.7 
32.6 
11.1 
4.4 
6.62 
1314 
Mood 
disorder 
(N=42) 
16.7 
26.6 
7 141 
wl 
5.67 
1665 
47.6 
31.1 
19.0 1 
28.6 1 
20.90 
1286 
19.0 
38.7 
14.31 
4.8 1 
10.67 
1164 
16.7 
33.7 
2.41 
4.81 
7.93 
1098 
Test 
statistics 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
x
2=5.14 
(p < 0.05) 
NS 
NS 
NS 
t= 2.41 
(p < 0.05) 
NS 
NS 
NS 
x
2 •= 5.69 
(p< 0.05) 
NS 
NS 
NS 
NS 
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SPSS/PC soft ware. The tests done were 
chi-square test (with Yates correction) and t test 
for parametric and non-parametric variables 
respectively. 
RESULTS 
The prevalence of extrapyramidal side 
effects including tardive dyskinesia in the total 
sample was 71%. Comparison of the prevalence 
of total side effects in schizophrenia (77.8%) 
and mood disorder (64.3%) was not significant. 
Comparison of the prevalence of individual side 
effects, mean age of onset, sex difference, time 
of onset and mean dose of neuroleptic received 
(chlorpromazine equivalent) between 
schizophrenia and mood disorder are given in 
table. 
DISCUSSION 
Though literature abounds with studies 
of neurological side effects of neuroleptic drugs, 
many questions are left unanswered. In India 
not many studies have been done on drug in-
duced movement disorders. In our study more 
than 70% of the patients treated with neurolep-
tics developed extrapyramidal side effects or 
tardive dyskinesia. This is in broad agreement 
with the literature (Glenberg, 1987; Davis et 
al., 1989). There was no significant difference 
in the prevalence between schizophrenia and 
mood disorder patients when all the side effects 
were considered together. Of the total patients, 
the individual side effects present were 54% 
(pseudoparkinsonism), 25% (akathisia), 17% 
(dystonia) and 17% (tardive dyskinesia). This 
too is similar to the rates reported previously 
(Fahn, 1984; Addonizio and Alexopoulose, 
1988). Except tardive dyskinesia the prevalence 
of dystonia,pseudoparki- nsonism and akathisia 
were equal in 2 groups. Tardive dyskinesia was 
found to be high in patients with mood disor-
der. There are plenty of reports showing that 
the prevalence of tardive dyskinesia is higher 
in mood disorder than in schizophrenia (Mukher-
jee et al., 1986; Caesey, 1988 & Dutta et al., 
1994). Major depression and bipolar disorder 
are risk factors for neuroleptic induced tardive 
dyskinesia. Even among schizophrenic patients 
a history of mood disorder in first-degree rela-
tive may heighten the risk of developing this 
syndrome (Wegnere.t al., 1985). 
When each side effect was analysed 
separately for each sex, an interesting factor 
which emerged was that pseudoparkinsonism 
was more common in female patients with di-
agnosis of mood disorder. Previous studies 
have reported a predilection for pseudoparkin-
sonism in elderly females (Caesey & Keepers, 
1988) but a correlation has not been reported 
with mood disorder. The gender predisposition 
of tardive dyskinesia in women and dystonia in 
men were not borne by this study. Similarly the 
correlation with age reported for dystonia (in 
young men), pseudoparkinsonism and tardive 
dyskinesia (in old age) was not seen in this 
study. Akathisia was found to be common in 
middle aged patients in the mood disorder 
group. There are reports showing that middle 
aged women are at increased risk for akathisia 
and its time course is similar to that for drug 
induced parkinsonism (Adler et al.,1989). 
Akathisia has been reported with lithium car-
bonate (Channabasavanna & Goswami, 1984) 
and tricyclic antidepressant therapy (Krishnan 
et al., 1984). Since mood disorder patients have 
received lithium or tricyclic antidepressants in 
addition to neuroleptics, this may be the rea-
son for the predilection for akathisia in middle 
aged mood disorder patients. 
In this study all side effects except tar-
dive dyskinesia were noted within an average 
period of less than 3 weeks. Probably this points 
to the fact that it is during the initial weeks of 
neuroleptic therapy that we should be vigilant 
on the search for side effects. If side effects 
are not promptly treated it may adversely 
affect the patients' compliance. As a group, 
schizophrenics received more chlorpromazine 
equivalent of neuroleptics than mood disorders 
patients, though it was not statistically 
significant. Despite receiving less neuroleptics, 
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tardive dyskinesia was significantly high in 
mood disorder patients. This again reiterates 
the fact that neuroleptic dosage and mood dis-
orders are the risk factors for the development 
of tardive dyskinesia. 
Except for tardive dyskinesia the 
question of differential side effect profile of 
neuroleptics in schizophrenia and mood disor-
der has not been addressed to in the literature. 
There are few reports concerning the 
prevalence of acute neuroleptic induced 
dystonia in schizophrenia and mania but there 
is no uniform consensus in the results as in 
tardive dyskinesia (Nasrallah et al., 1988; 
Remington et al., 1990; Khanna et al., 1992; 
Pandey et al., 1992). Our study has shown three 
differences between schizophrenia and mood 
disorders, viz. higher incidence of parkinsonism 
in female mood disorder patients, higher 
incidence of akathisia in middle aged mood 
disorder patients and higher incidence of 
tardive dyskinesia in mood disorder patients. 
This generally shows that patients in mood 
disorder group are more vulnerable to the 
development of neuroleptic induced neurologi-
cal side effects. Apparently, the large dose of 
neuroleptics received by this group in addition 
to the mood stablising drug could be the 
reason for the high prevalence of neuroleptic 
induced neurological side effects in mood 
disorder patients. We believe that future 
studies should address this question of 
differential side effects profile in schizophrenia 
and mood disorder patients. 
Before concluding, the methodological 
limitations of this study have to be considered. 
The retrospective chart survey method 
employed would mean that the prevalence rates 
obtained may be an underestimation, as the 
same side effects may have been missed by 
the clinician who was not especially looking for 
it. This would be particularly true for akathisia 
which is often missed by the clinician (Levinson 
& Simpson, 1987) and for milder forms of tar-
dive dyskinesia. Use of specific rating scales 
to measure the various, side effects and a pro-
spective design would be ideal. The period of 
follow-up of one year is too short for the study 
of tardive dyskinesia which requires long term 
follow-up. 
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